×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
BGNE – beigene, ltd. - american depositary shares (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
BGNE
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/27
06:04 am
bgne
TEVIMBRA Approved in U.S. for First-line Treatment of Gastric and Gastroesophageal Junction Cancers in Combination with Chemotherapy [Yahoo! Finance]
Low
Report
TEVIMBRA Approved in U.S. for First-line Treatment of Gastric and Gastroesophageal Junction Cancers in Combination with Chemotherapy [Yahoo! Finance]
12/27
06:00 am
bgne
TEVIMBRA Approved in U.S. for First-line Treatment of Gastric and Gastroesophageal Junction Cancers in Combination with Chemotherapy
Low
Report
TEVIMBRA Approved in U.S. for First-line Treatment of Gastric and Gastroesophageal Junction Cancers in Combination with Chemotherapy
12/24
06:18 am
bgne
With 45% institutional ownership, BeiGene, Ltd. (NASDAQ:BGNE) is a favorite amongst the big guns [Yahoo! Finance]
Low
Report
With 45% institutional ownership, BeiGene, Ltd. (NASDAQ:BGNE) is a favorite amongst the big guns [Yahoo! Finance]
12/23
06:00 am
bgne
BeiGene to Change Nasdaq Ticker Symbol to “ONC” on January 2; Present at 43rd Annual J.P. Morgan Healthcare Conference
Low
Report
BeiGene to Change Nasdaq Ticker Symbol to “ONC” on January 2; Present at 43rd Annual J.P. Morgan Healthcare Conference
12/12
07:30 pm
bgne
BeiGene Announces Global Licensing Agreement for MAT2A Inhibitor
Medium
Report
BeiGene Announces Global Licensing Agreement for MAT2A Inhibitor
12/9
08:32 pm
bgne
BeiGene Advances Leadership in CLL at ASH 2024 with New Data From Its Hematology Franchise Including BRUKINSA® and Novel Pipeline Assets [Yahoo! Finance]
Medium
Report
BeiGene Advances Leadership in CLL at ASH 2024 with New Data From Its Hematology Franchise Including BRUKINSA® and Novel Pipeline Assets [Yahoo! Finance]
12/9
08:30 pm
bgne
BeiGene Advances Leadership in CLL at ASH 2024 with New Data From Its Hematology Franchise Including BRUKINSA® and Novel Pipeline Assets
Medium
Report
BeiGene Advances Leadership in CLL at ASH 2024 with New Data From Its Hematology Franchise Including BRUKINSA® and Novel Pipeline Assets
12/4
06:12 am
bgne
BeiGene and CLL Society Partner to Advance Test Before Treat™ Campaign, Promoting Biomarker Testing to Improve Patient Outcomes in CLL [Yahoo! Finance]
Medium
Report
BeiGene and CLL Society Partner to Advance Test Before Treat™ Campaign, Promoting Biomarker Testing to Improve Patient Outcomes in CLL [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
11/12/2024
06:00 am
bgne
beigene, ltd. - american depositary shares
MISS
Report
-1.3%
beigene, ltd. - american depositary shares
8/7/2024
06:00 am
bgne
beigene, ltd. - american depositary shares
BEAT
Report
2.7%
beigene, ltd. - american depositary shares
5/8/2024
06:00 am
bgne
beigene, ltd. - american depositary shares
BEAT
Report
6.1%
beigene, ltd. - american depositary shares
2/26/2024
06:00 am
bgne
beigene, ltd. - american depositary shares
BEAT
Report
2.0%
beigene, ltd. - american depositary shares
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
12/23
06:06 am
bgne
Form 8-K BeiGene, Ltd. For: Dec 23
Low
Report
Form 8-K BeiGene, Ltd. For: Dec 23
12/17
05:02 pm
bgne
Form 4 BeiGene, Ltd. For: Dec 14 Filed by: OYLER JOHN
Low
Report
Form 4 BeiGene, Ltd. For: Dec 14 Filed by: OYLER JOHN
12/12
05:18 pm
bgne
Form 4 BeiGene, Ltd. For: Dec 10 Filed by: Wang Xiaodong
Medium
Report
Form 4 BeiGene, Ltd. For: Dec 10 Filed by: Wang Xiaodong
12/10
09:31 pm
bgne
Form SC 13D/A BeiGene, Ltd. Filed by: BAKER BROS. ADVISORS LP
Low
Report
Form SC 13D/A BeiGene, Ltd. Filed by: BAKER BROS. ADVISORS LP
12/10
09:26 pm
bgne
Form 4 BeiGene, Ltd. For: Dec 09 Filed by: BAKER JULIAN
Low
Report
Form 4 BeiGene, Ltd. For: Dec 09 Filed by: BAKER JULIAN
12/10
08:20 pm
bgne
Form 4 BeiGene, Ltd. For: Dec 06 Filed by: Wu Xiaobin
Low
Report
Form 4 BeiGene, Ltd. For: Dec 06 Filed by: Wu Xiaobin
12/10
04:27 pm
bgne
Form 144 BeiGene, Ltd. Filed by: Wang Xiaodong
Low
Report
Form 144 BeiGene, Ltd. Filed by: Wang Xiaodong
12/10
06:03 am
bgne
Form 8-K BeiGene, Ltd. For: Dec 09
Medium
Report
Form 8-K BeiGene, Ltd. For: Dec 09
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
10/31
Amgen to take 20.5% stake in BeiGene to expand in China [Reuters (UK)]
37.2%
5/9 Q1/2019 3/31/2019 EPS -2.810 ZacksConsensus -3.090 ActVsEst 0.280 - Beat 10.7%
5/14 Beigene Ltd (NASDAQ: BGNE) had its price target raised by analysts at Morgan Stanley from $200.00 to $210.00. They now have an "overweight" rating on the stock. 8.1%
4/13 BeiGene Announces that the Phase 3 Trial of Tislelizumab Combined with Chemotherapy in Patients with First-Line Non-Squamous Non-Small Cell Lung Cancer Met the Primary Endpoint of Progression-Free Survival at Interim Analysis 6.6%
3/13 Beigene Ltd (NASDAQ: BGNE) was upgraded by analysts at Macquarie from an "underperform" rating to a "neutral" rating. 6.2%
10/16 Beigene Ltd (NASDAQ: BGNE) had its "buy" rating re-affirmed by analysts at Cowen Inc. They now have a $170.00 price target on the stock. 5.5%
12/16 Week In Review: Alphamab Raises $234 Million In Hong Kong IPO; Climbs 35% In First Trading Session [Seeking Alpha] 4.5%
11/18 Form 4 BeiGene, Ltd. For: Nov 15 Filed by: Wu Xiaobin 4.0%
9/8 BeiGene to Hold Conference Call and Webcast on September 8, 2019 at 7:00 p.m. ET to Provide Corporate Update 4.0%
9/11 INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against BeiGene, Ltd. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm 4.0%
5/9 Q1/2019 3/31/2019 EPS -2.810 ZacksConsensus -3.090 ActVsEst 0.280 - Beat 10.7%
5/14 Beigene Ltd (NASDAQ: BGNE) had its price target raised by analysts at Morgan Stanley from $200.00 to $210.00. They now have an "overweight" rating on the stock. 8.1%
4/13 BeiGene Announces that the Phase 3 Trial of Tislelizumab Combined with Chemotherapy in Patients with First-Line Non-Squamous Non-Small Cell Lung Cancer Met the Primary Endpoint of Progression-Free Survival at Interim Analysis 6.6%
3/13 Beigene Ltd (NASDAQ: BGNE) was upgraded by analysts at Macquarie from an "underperform" rating to a "neutral" rating. 6.2%
10/16 Beigene Ltd (NASDAQ: BGNE) had its "buy" rating re-affirmed by analysts at Cowen Inc. They now have a $170.00 price target on the stock. 5.5%
12/16 Week In Review: Alphamab Raises $234 Million In Hong Kong IPO; Climbs 35% In First Trading Session [Seeking Alpha] 4.5%
11/18 Form 4 BeiGene, Ltd. For: Nov 15 Filed by: Wu Xiaobin 4.0%
9/8 BeiGene to Hold Conference Call and Webcast on September 8, 2019 at 7:00 p.m. ET to Provide Corporate Update 4.0%
9/11 INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against BeiGene, Ltd. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm 4.0%
TOP News Decliners
9/26
BeiGene Announces Clinical Data on Tislelizumab and Pamiparib to Be Presented at the European Society for Medical Oncology (ESMO) Congress 2019
-12.8%
4/30 Form 4 BeiGene, Ltd. For: Apr 29 Filed by: Huang Jane -8.3%
9/5 Form 4 BeiGene, Ltd. For: Sep 03 Filed by: Huang Jane -8.0%
6/5 BeiGene to Present at the Goldman Sachs 40th Annual Global Healthcare Conference -7.2%
6/14 BeiGene Announces Updated Results from a Pivotal Phase 2 Study of Tislelizumab in Chinese Patients with Relapsed or Refractory Classical Hodgkin Lymphoma at the 24th Congress of the European Hematology Association (EHA) -6.9%
9/9 BeiGene rebounds from bearish report-stoked selloff, up 8% [Seeking Alpha] -6.3%
12/16 BeiGene Announces Results of Phase 3 ASPEN Trial of Zanubrutinib Compared to Ibrutinib for the Treatment of Patients with Waldenström’s Macroglobulinemia -6.2%
4/29 BeiGene Announces Clinical Data to Be Presented at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting -5.8%
3/3 Beigene Ltd (NASDAQ: BGNE) had its "buy" rating re-affirmed by analysts at Cowen Inc. They now have a $200.00 price target on the stock. -5.7%
3/25 BeiGene Announces Supply Update for ABRAXANE® in China -5.6%
4/30 Form 4 BeiGene, Ltd. For: Apr 29 Filed by: Huang Jane -8.3%
9/5 Form 4 BeiGene, Ltd. For: Sep 03 Filed by: Huang Jane -8.0%
6/5 BeiGene to Present at the Goldman Sachs 40th Annual Global Healthcare Conference -7.2%
6/14 BeiGene Announces Updated Results from a Pivotal Phase 2 Study of Tislelizumab in Chinese Patients with Relapsed or Refractory Classical Hodgkin Lymphoma at the 24th Congress of the European Hematology Association (EHA) -6.9%
9/9 BeiGene rebounds from bearish report-stoked selloff, up 8% [Seeking Alpha] -6.3%
12/16 BeiGene Announces Results of Phase 3 ASPEN Trial of Zanubrutinib Compared to Ibrutinib for the Treatment of Patients with Waldenström’s Macroglobulinemia -6.2%
4/29 BeiGene Announces Clinical Data to Be Presented at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting -5.8%
3/3 Beigene Ltd (NASDAQ: BGNE) had its "buy" rating re-affirmed by analysts at Cowen Inc. They now have a $200.00 price target on the stock. -5.7%
3/25 BeiGene Announces Supply Update for ABRAXANE® in China -5.6%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: